Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rare MSI-H hepatoid adenocarcinoma of the colon with BRAF V600E mutation achieving long-term disease-free survival after adjuvant envafolimab: a case report.

Frontiers in immunology - 1 Jan 2025

Fan Shaoqing, Meng Qingyu, Zhao Zeming, Niu Wenbo

Abstract excerpt

Case presentation: Microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) is characterized by high tumor mutational burden and strong immunogenicity, making it responsive to immune checkpoint inhibitors. Hepatoid adenocarcinoma (HAC) of the colon is an exceptionally rare and aggressive subtype, often resistant to conventional chemotherapy. We report a 77-year-old woman...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Monoclonal, Humanized

Share to Colonic Neoplasms

Share to Disease-Free Survival

Share to Immune Checkpoint Inhibitors

Share to Microsatellite Instability

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 41346621
DOI: 10.3389/fimmu.2025.1698410
PMCID: PMC12672860

Genes

BRAF
MLH1
MSH6
PMS2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rare MSI-H hepatoid adenocarcinoma of the colon with BRAF V600E mutation achieving long-term disease-free survival after adjuvant envafolimab: a case report.PMID 41346621Read ↗

Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancerSemantic proximity Read ↗

The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancersSemantic proximity Read ↗

Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer LandscapeSemantic proximity Read ↗

Unraveling Resistance to Immunotherapy in MSI-High Colorectal CancerSemantic proximity Read ↗

Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.Semantic proximity Read ↗

Microsatellite Phenotype as a Guide for Immunotherapy in Colorectal Cancer: Current Status and Future Perspectives.Semantic proximity Read ↗

The Prevalence and Prognosis of Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Adenocarcinomas in the United StatesSemantic proximity Read ↗

Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch SyndromeSemantic proximity Read ↗

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicineSemantic proximity Read ↗

Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal CancersSemantic proximity Read ↗

Ultra-Hypermutation Driven by POLE Mutation in Metastatic Colorectal Cancer: A Case for Immunotherapy Without dMMRSemantic proximity Read ↗

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite InstabilitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.